Genetic Ablation of PDGF-Dependent Signaling Pathways Abolishes Vascular Remodeling and Experimental Pulmonary Hypertension-Reference-Cited by-同舟云学术

Genetic Ablation of PDGF-Dependent Signaling Pathways Abolishes Vascular Remodeling and Experimental Pulmonary Hypertension

Published:2015-05 Issue:5 Volume:35 Page:1236-1245
ISSN:1079-5642
Container-title:Arteriosclerosis, Thrombosis, and Vascular Biology
language:en
Short-container-title:Arterioscler Thromb Vasc Biol.

Author:

ten Freyhaus Henrik¹,Berghausen Eva M.¹,Janssen Wiebke¹,Leuchs Maike¹,Zierden Mario¹,Murmann Kirsten¹,Klinke Anna¹,Vantler Marius¹,Caglayan Evren¹,Kramer Tilmann¹,Baldus Stephan¹,Schermuly Ralph T.¹,Tallquist Michelle D.¹,Rosenkranz Stephan¹

Affiliation:

1. From the Klinik III für Innere Medizin, Herzzentrum der Universität zu Köln, Cologne, Germany (H.t.F., E.M.B., M.L., M.Z., A.K., M.V., E.C., T.K., S.B., S.R.); Center for Molecular Medicine Cologne (CMMC) (H.t.F., E.M.B., M.L., M.Z., A.K., M.V., E.C., S.B., S.R.), and Cologne Cardiovascular Research Center (CCRC) (H.t.F., A.K., S.B., S.R.), University of Cologne, Cologne, Germany; University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany (W.J., K.M., R.T.S.); and Center for...

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference38 articles.

1. Predicting Survival in Pulmonary Arterial Hypertension

2. Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era

3. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry

4. Inflammation, Growth Factors, and Pulmonary Vascular Remodeling

5. Cellular and Molecular Basis of Pulmonary Arterial Hypertension

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel PDGFR inhibitor WQ-C-401 prevents pulmonary vascular remodeling in rats with monocrotaline-induced pulmonary arterial hypertension;Experimental Cell Research;2024-08

2. Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial;The Lancet Respiratory Medicine;2024-07

3. C-type natriuretic peptide/cGMP/FoxO3 signaling attenuates hyperproliferation of pericytes from patients with pulmonary arterial hypertension;Communications Biology;2024-06-06

4. IMPAHCT: A randomized phase 2b/3 study of inhaled imatinib for pulmonary arterial hypertension;Pulmonary Circulation;2024-01

5. Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension;International Journal of Molecular Sciences;2023-08-10